Surat Samachar

Atopic Dermatitis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies – Pfizer, Kymera

 Breaking News
  • No posts were found

Atopic Dermatitis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies – Pfizer, Kymera

April 11
20:44 2023
Atopic Dermatitis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies,  Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Pfizer, Kymera
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Atopic Dermatitis pipeline constitutes key companies continuously working towards developing Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Atopic Dermatitis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atopic Dermatitis Market.

 

Some of the key takeaways from the Atopic Dermatitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atopic Dermatitis treatment therapies with a considerable amount of success over the years. 
  • Atopic Dermatitis companies working in the treatment market are  Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others, are developing therapies for the Atopic Dermatitis treatment 
  • Emerging Atopic Dermatitis therapies such as – PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others are expected to have a significant impact on the Atopic Dermatitis market in the coming years.   
  • In November 2022, the first cohort of the Phase IIa clinical study for AB-101a, a topical treatment option for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old, has finished, according to an announcement from Alphyn Biologics. Patients without bacterial infections, which are occasionally linked to AD, were enrolled in the first cohort. Top-line outcomes are anticipated in around eight weeks.
  • In September 2022, Patients in a Phase Ib trial to assess the safety and effectiveness of si-544 in those with mild to severe atopic dermatitis have started receiving doses, according to selectION
  • In July 2022, According to 255 patients in its ongoing pivotal trial for its lead product candidate CBP-201 to treat adult patients with moderate-to-severe atopic dermatitis (AD), Connect Biopharma Holdings has received confirmation from the Center for Drug Evaluation of the National Medical Products Administration (CDE) that it is permitted to conduct primary analysis of the trial. Link Biopharma hence anticipates reporting this trial’s top-line results earlier than anticipated, by year’s end
  • In May 2022, Brickell Biotech announced that the first subjects were dosed in the single ascending dose of Phase I clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis. BBI-02 is a potential first-in-class, highly selective, orally bioavailable small molecule DYRK1A inhibitor that aims to restore immune balance through modulating adaptive and innate immune responses in patients with autoimmune and inflammatory diseases
  • In January 2021, Arcutis Biotherapeutics initiated a Phase III trial titled “A Phase III, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis

 

Atopic Dermatitis Overview

Atopic Dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts inearly childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means‘skin’ and ‘itis’ means ‘inflammation.’

 

Get a Free Sample PDF Report to know more about Atopic Dermatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight

 

Emerging Atopic Dermatitis Drugs Under Different Phases of Clinical Development Include:

  • PF 07242813: Pfizer
  • Amlitelimab: Kymab
  • KT-474: Kymera Therapeutics
  • BX 005: BiomX
  • BEN2293: BenevolentAI
  • LP 0145: LEO Pharma
  • MEDI3506: AstraZeneca
  • Q301: Qurient
  • SB011: Sterna Biologicals
  • Tradipitant: Vanda Pharmaceuticals
  • Roflumilast: Arcutis Biotherapeutics

 

Route of Administration

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Atopic Dermatitis Pipeline Therapeutics Assessment

  • Atopic Dermatitis Assessment by Product Type
  • Atopic Dermatitis By Stage and Product Type
  • Atopic Dermatitis Assessment by Route of Administration
  • Atopic Dermatitis By Stage and Route of Administration
  • Atopic Dermatitis Assessment by Molecule Type
  • Atopic Dermatitis by Stage and Molecule Type

 

DelveInsight’s Atopic Dermatitis Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Atopic Dermatitis product details are provided in the report. Download the Atopic Dermatitis pipeline report to learn more about the emerging Atopic Dermatitis therapies

 

Some of the key companies in the Atopic Dermatitis Therapeutics Market include:

Key companies developing therapies for Atopic Dermatitis are – Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, Evommune, Inc., Fresh Tracks Therapeutics, Biosion, Chia Tai Tianqing Pharmaceutical, Reistone Biopharma Company Limited, JW Pharmaceutical, Oneness Biotech, Alphyn Biologics, selectION, UNION Therapeutics, Ichnos Sciences, and others.

 

Atopic Dermatitis Pipeline Analysis:

The Atopic Dermatitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
  • Atopic Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Atopic Dermatitis drugs and therapies

 

Atopic Dermatitis Pipeline Market Drivers

  • Rising prevalence of Atopic Dermatitis, escalating expenditure on health care, potential Emerging Therapies are some of the important factors that are fueling the Atopic Dermatitis Market.

 

Atopic Dermatitis Pipeline Market Barriers

  • However, over-the-counter medications, outdated treatment recommendations, poor prognosis and treatment adherence and other factors are creating obstacles in the Atopic Dermatitis Market growth.

 

Scope of Atopic Dermatitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Atopic Dermatitis Companies: Pfizer, Kymera Therapeutics, BenevolentAI, AstraZeneca, Qurient, Sterna Biologicals, Vanda Pharmaceuticals, Arcutis Biotherapeutics, and others
  • Key Atopic Dermatitis Therapies: PF 07242813, KT-474, BEN2293, MEDI3506, Q301, SB011, Tradipitant, Roflumilast, and others
  • Atopic Dermatitis Therapeutic Assessment: Atopic Dermatitis current marketed and Atopic Dermatitis emerging therapies
  • Atopic Dermatitis Market Dynamics: Atopic Dermatitis market drivers and Atopic Dermatitis market barriers 

 

Request for Sample PDF Report for Atopic Dermatitis Pipeline Assessment and clinical trials

 

Table of Contents

1

Atopic Dermatitis Report Introduction

2

Atopic Dermatitis Executive Summary

3

Atopic Dermatitis Overview

4

Atopic Dermatitis- Analytical Perspective In-depth Commercial Assessment

5

Atopic Dermatitis Pipeline Therapeutics

6

Atopic Dermatitis Late Stage Products (Phase II/III)

7

Atopic Dermatitis Mid Stage Products (Phase II)

8

Atopic Dermatitis Early Stage Products (Phase I)

9

Atopic Dermatitis Preclinical Stage Products

10

Atopic Dermatitis Therapeutics Assessment

11

Atopic Dermatitis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Atopic Dermatitis Key Companies

14

Atopic Dermatitis Key Products

15

Atopic Dermatitis Unmet Needs

16 

Atopic Dermatitis Market Drivers and Barriers

17

Atopic Dermatitis Future Perspectives and Conclusion

18

Atopic Dermatitis Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services